AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02461069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
Study NCT00415818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-MUC1-IL2
Description: MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first.
Study NCT00415818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1st line Chemotherapy
Study NCT00415818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st line Chemotherapy
Study NCT03018080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV (in the vein) on day 1 of a 21 day cycle
Study NCT03018080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV (in the vein) on days 1 and 8 of a 21 day cycle
Study NCT04543149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric immunophenotyping
Description: To evaluate T cell subsets and monocyte
Study NCT03021083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONSYS Patch
Description: Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
Study NCT04105296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO+ES
Description: 6 months of exoskeleton training with epidural stimulation.
Study NCT00934336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
Study NCT04332081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy (HBOT)
Description: The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
Study NCT00624936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
Study NCT00624936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
Study NCT01791673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound glaucoma treatment
Description: Ultrasound glaucoma treatment with EYEOP1 device
Study NCT03226769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear™
Description: Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
Study NCT03226769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermalon Dry Eye Compress
Description: Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
Study NCT04007120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered once daily over two days
Study NCT02307279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Study NCT02307279 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01211769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
Study NCT01211769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone + Placebo
Description: A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
Study NCT01439503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms.
Study NCT01271764 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no drug
Description: The role of G9a protein in patients with endometrial cancer
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Study NCT01890798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
Study NCT01689285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir tablet
Description: 16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorpheniramine
Description: In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
Study NCT02065336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chlorpheniramine
Description: In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
Study NCT01877538 — intervention group
Intervention type: OTHER
Intervention: [11C]donepezil PET
Description: Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
Study NCT02125201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
Study NCT02125201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
Study NCT03886532 — intervention group
Intervention type: OTHER
Intervention: Medical Marijuana
Description: registry and blood samples
Study NCT02432261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone® /testosterone gel
Description: Nestorone® /testosterone combined gel
Study NCT02432261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone only gel
Description: Testosterone only gel
Study NCT00210626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROCRIT
Description: 40,000 IU/mL/week for max of 12 weeks
Study NCT00210626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40,000 IU/mL/week for max of 12 weeks
Study NCT00969839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaLign Intramedullary Fixation System
Description: Intramedullary fixation of broken humerus
Study NCT03238768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intravenous Nutrition
Description: Increased macronutrients for first 7 days
Study NCT03238768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intravenous Nutrition
Description: Standard macronutrients for first 7 days
Study NCT01215123 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
Study NCT04449159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinh Wellness Collagen
Description: Vinh Wellness Collagen is hydrolyzed collagen
Study NCT04449159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01885637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transition program
Description: Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
Study NCT03377556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03377556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03377556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT03474341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: * Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease
Study NCT03474341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET-CT
Description: * According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time
Study NCT00544583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted sutures
Description: Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
Study NCT00544583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous sutures
Description: Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
Study NCT01689285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir oral solution
Description: 16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
Study NCT01092988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 2100
Description: MR guided focused ultrasound
Study NCT03856814 — intervention group
Intervention type: DEVICE
Intervention: ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation
Description: Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
Study NCT04934878 — intervention group
Intervention type: BIOLOGICAL
Intervention: Referral information
Description: first visit to our hospital/transfer from another hospital
Study NCT03474341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopy
Description: Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
Study NCT03235401 — intervention group
Intervention type: OTHER
Intervention: 37-items questionnaire
Description: Patient will answer the PAH-DBoQ questionnaire
Study NCT00460577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumerate
Description: 12 micrograms stat (twice if necessary). Inhaled via aerolizer
Study NCT00460577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenoterol/ipratropium bromide
Description: 0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
Study NCT01436604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage.
Study NCT02469051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Breathhold SPECT-MPI
Description: Respiratory triggered SPECT myocardial perfusion imaging
Study NCT02469051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard freebreathing SPECT-MPI
Description: Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
Study NCT02469051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary CT angiography
Description: Clinically indicated coronary CT angiography serving as standard of reference
Study NCT02113540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT02961777 — intervention group
Intervention type: OTHER
Intervention: implementation of care pathway
Description: implementation of a care pathway
Study NCT00223743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
Study NCT03474341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: * Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT
Study NCT04611503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subretinal injection of rAAV.hPDE6A
Description: The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg).
Study NCT03264599 — intervention group
Intervention type: DEVICE
Intervention: transabdominal ultrasound
Description: 2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
Study NCT04232475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 minute of stair climbing and descending
Description: 1 minute of stair climbing and descending
Study NCT03491462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
Study NCT03491462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matched placebo capsules taken 3 times daily
Study NCT01575834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month (QM)
Study NCT01575834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month (QM)
Study NCT01575834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months (Q6M)
Study NCT04101305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IsoPic
Description: Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
Study NCT01886924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Computer MI for Smoking Cessation
Description: Brief computer MI intervention to motivate tobacco quitline use
Study NCT01886924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Control
Description: Computer delivered nutrition education control condition
Study NCT03979573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multiparametric MRI
Description: Multiparametric prostate MRI (mp-MRI)
Study NCT03979573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Radiomics
Description: Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
Study NCT03979573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR-guided Biopsy
Description: MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
Study NCT03979573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular Markers
Description: Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
Study NCT02361320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
Study NCT02361320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
Study NCT04263311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW
Description: Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
Study NCT01059565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Study NCT01059565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Study NCT02525874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Initial oral dose for 7 days with maintenance dose thereafter